GSA Capital Partners LLP raised its holdings in shares of Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) by 124.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,878 shares of the company’s stock after buying an additional 43,144 shares during the quarter. GSA Capital Partners LLP owned about 0.14% of Hookipa Pharma worth $178,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of HOOK. Banque Cantonale Vaudoise bought a new stake in shares of Hookipa Pharma during the first quarter valued at approximately $46,000. Redmile Group LLC increased its position in shares of Hookipa Pharma by 29.3% during the fourth quarter. Redmile Group LLC now owns 2,385,136 shares of the company’s stock valued at $5,557,000 after purchasing an additional 540,831 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Hookipa Pharma by 210.5% during the fourth quarter. Acadian Asset Management LLC now owns 252,256 shares of the company’s stock valued at $587,000 after purchasing an additional 171,019 shares during the period. 53.98% of the stock is currently owned by institutional investors and hedge funds.
Hookipa Pharma Price Performance
Hookipa Pharma stock opened at $1.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $76.59 million, a P/E ratio of -0.74 and a beta of 0.85. The business’s fifty day moving average is $1.60 and its two-hundred day moving average is $1.69. Hookipa Pharma Inc has a 52 week low of $1.25 and a 52 week high of $6.98.
Wall Street Analyst Weigh In
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
- Get a free copy of the StockNews.com research report on Hookipa Pharma (HOOK)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.